Satin Creditcare — a cheap, scarred microlender
Satin Creditcare Network Ltd
Snapshot
Satin Creditcare lends tiny, unsecured loans — ₹30,000-odd at a time — to poor rural women in groups, mostly across north and central India. It is one of India’s larger microfinance lenders (the third-biggest by loan book), with ₹15,275 crore of loans, plus small housing-finance, MSME and technology arms. Market cap ₹2,601 cr, share price ₹235 (52-week range ₹133–247), trading on 7.8× earnings and 0.91× book value (book value ₹259). RoE 12.3%, RoCE 13.8%, no dividend — ever.
What kind of animal is it? A scarred, cyclical, capital-hungry lender — closer to a “bruised survivor” than a quality compounder. Cheap for a reason, but cheap. As of 2026-06-20, from screener snapshot.
The verdict in one box
| Lens | Result |
|---|---|
| QGLP score | 14 / 25 (Quality 5/12 · Growth 3.5/6 · Longevity 3.5/5 · Price 2/2) |
| Buffett rubric | 2.5 / 10 PASS |
| Business bucket | Good-leaning-Gruesome — a lender whose through-cycle returns don’t durably clear the cost of its risk |
| Wealth-creator type | Transitory · Volatile (fails the consistency test badly) |
| Economic Profit | ≈ ₹9 cr at 12% cost of equity (RoE 12.3% − CoE 12% on ₹2,863 cr net worth) — essentially breakeven this year; negative through the cycle |
| Margin-of-safety price band | ₹200–235 = cheap (below book); ₹260–300 = fair (~1.0–1.15× book); >₹340 = demanding. CMP ₹235 is cheap-to-fair |
A Good-leaning-Gruesome business that is not a durable wealth creator, currently priced cheap versus its book — the price is the whole attraction, not the quality.
In plain English
Imagine a business that lends small sums of money to very poor people, with no collateral, and gets paid back almost entirely on trust and weekly group meetings. In good years it earns a fat spread and looks wonderful. Then every four or five years something hits the village all at once — a cash ban (2016), a pandemic (2020), or borrowers quietly taking loans from five lenders at the same time until the whole web snaps (2024–25) — and a year of profit, sometimes the equity itself, goes up in smoke. That is microfinance. It is not a bad business run by bad people. It is a fragile business, full stop. The boat takes on water on a schedule.
Satin is one of the older boats — 35 years, run by the same founder, Dr H.P. Singh, who has steered it through all three storms. That longevity is real and it counts. The latest storm (FY25) was brutal for the whole sector, and Satin came through it better than most of its peers — its bad-loan ratio (3.1%) and credit losses (3.8% of the book) were milder than the carnage at Fusion or Spandana. The March 2026 quarter was a barnstormer: profit of ₹162 cr versus ₹22 cr a year earlier, helped by collections snapping back to ~99.9% and credit costs falling. The sector has clearly turned the corner — industry bad loans have halved, lending is growing again for the first time in seven quarters.
So where’s the catch? Two places. First, this is not a compounding machine. Add up Satin’s profits over the last decade and you get a saw-blade, not a staircase: a loss in FY21, profit down 76% in FY23, down 57% in FY25. Over the full cycle it earns a return on its owners’ money of roughly 9% — below what owners should demand for taking this much risk. In plain terms: across a whole cycle, it has not reliably created wealth above the cost of the worry. It also keeps raising fresh equity (diluting owners) and has never once paid a dividend despite “repeated profits.”
Second — and this is the tension — the price already knows a lot of this. The stock trades below its book value and at under 8× earnings. That is a genuinely fearful price for a business that is recovering. But it has already climbed ~77% off its ₹133 low, so the easy “it’s not dead after all” money has been made. What you’re buying now is a cheap, mediocre-quality lender at the cheap-to-fair line, betting the recovery keeps going and the next blow-up is a few years away. That can work as a cyclical, value, mean-reversion trade. It is not a “buy it and forget it for 20 years” stock. The two are different games, and it’s important not to confuse them.
Sitting down with the management
If Buffett and Raamdeo Agrawal sat across from Dr H.P. Singh for an afternoon, I think they’d come away respecting the man and worrying about the business.
Singh built Satin in 1990. He’s a chartered accountant and lawyer who noticed, while auditing a company, that small East-Delhi shopkeepers couldn’t borrow for something as basic as a generator — and built a daily-collection lender around their cash flows. Thirty-five years later he’s still Chairman and MD. That is a genuine founder with genuine domain mastery, and his survival record speaks: demonetisation in 2016 cratered Satin’s collections from 99% to 78% and put three-quarters of the book at risk, and he brought it back to profit within a year. He did the same after COVID and again now. “Longevity in this sector means something specific,” he told the latest call. “It means you have been tested repeatedly and you have come back stronger each time.” That’s not spin — it’s the literal record. His daughter Aditi Singh is now Chief Strategy Officer, and the senior team averages 10+ years at the firm. The culture is real and the bench is deeper than most MFIs.
On candor, he scores well. In FY25’s awful year he guided credit cost of 4.5–5.0% and delivered 4.6% — he hit his own number in a year when many peers blew through theirs. He talks plainly about sector stress rather than hiding it. When an analyst pushed on whether the blowout Q4 profit was a one-off, the team conceded a chunk came from securitisation income and treasury/forex gains (a ₹144 cr “gain on derecognition” line) while insisting the core had genuinely improved — that’s a reasonably honest answer, though it’s worth remembering the Q4 sparkle is flattered by those items.
Where the masters would frown is capital allocation and treatment of owners. Satin has raised equity again and again — a ₹250 cr placement in 2016, ~₹150 cr in 2017, a rights issue in 2020 — and the founder’s own stake has drifted down from ~42% to 36%. The share count has tripled in a decade. Reinvesting all profits and tapping owners for more, while earning a through-cycle return below the cost of capital, is the opposite of the one-dollar test passing cleanly: each rupee retained has not reliably become a rupee of market value (the stock trades below book). And zero dividends, ever, despite reported profits — for a minority owner, that’s a real knock. The subsidiary push (housing, MSME, an AIF fund, even a quantum-cryptography tech startup) is partly sensible diversification and partly the early scent of empire-building; the housing and MSME arms are real and growing fast, but they’re still small and unproven as earners of the diluted capital.
No serious governance red flags fired: no SEBI/RBI actions, no auditor qualifications, no promoter pledging surfaced, capital adequacy is fortress-grade (CRAR ~25%), the board has added independent directors, and ICRA rates it A (stable). The forensic “credit P&L, debit balance sheet” test doesn’t apply cleanly to a lender (operating cash flow is structurally negative because the loan book grows), but provisioning looks adequate — Stage-3 coverage 73%, provisions above the RBI minimum.
Would they shake hands? On the man, probably yes — mission-driven, durable, straight. On the business as a wealth machine, no — the dilution, the never-a-dividend, and the sub-cost-of-capital returns are exactly what Buffett means by a good rower in a leaky boat. What would change their mind: two clean cycles of mid-teens RoE with no fresh equity raise, and the first dividend.
What’s on the horizon (live-issues tracker)
① THE CRUX — Has the microfinance cycle truly turned, or is this the calm between blow-ups?
This investment works if and only if the MFI asset-quality cycle has genuinely bottomed AND the new guardrails make the next blow-up milder than the last.
The mechanism, in plain terms. Microfinance has no real moat and one recurring disease: borrower over-leverage. Everyone lends the same uncollateralised ₹30,000 to the same poor woman at the same ~24% rate. When times are good, five lenders each give her a loan; she’s now borrowed far more than she can repay, and the whole house of cards stands only as long as someone keeps refinancing. When credit tightens — an election, a drought, a state ordinance — the refinancing stops and everyone’s book sours at once. It is not like a bank with collateral to seize; the only security is the borrower’s willingness and ability to pay. The analogy that fits: it’s less like secured lending and more like a crowded payday-loan market with no credit ceiling — and the fix the regulator has applied (a hard cap of ₹2 lakh total exposure per borrower and no more than 3–4 lenders each) is the equivalent of finally putting a ceiling on how deep any one borrower can dig the hole. That is the genuinely new thing this cycle, and it’s why the recovery may be more durable than past ones.
How it’s going — 🟢 turning, with the scar still fresh. The hard data says the worst is past. Per the industry body MFIN’s latest report, the sector’s loan book grew over 3% in the March-2026 quarter — the first growth in seven quarters — and the key stress metric (loans 31–180 days overdue) fell from 6.1% a year ago to 2.0%, back to pre-crisis levels. Rating agency ICRA expects sector credit costs to fall from a 7.2% peak to 3–3.5% by FY27. Satin itself: bad loans 3.1%, collections ~99.9%, credit cost down to 3.8% (FY26) heading for a guided 3.0–3.5% (FY27). The arc across Satin’s own calls — credit cost guided and met in the worst year, then steadily falling — is the most reassuring evidence here.
The named competition / where the damage lands. This crux is about the fee/spread and the cycle, not market-share theft (Satin is actually gaining share versus weaker peers). The relevant map is the survivor pecking order:
| Lender | FY26 AUM | RoE | Asset quality through the cycle | Read |
|---|---|---|---|---|
| CreditAccess Grameen | ₹29,590 cr | ~10–11% (cyclically low; ~18–20% normal) | Cleanest, best-run | The gold standard; trades at ~2.9× book |
| Satin Creditcare | ₹15,275 cr | 12.3% | Milder hit than most; GNPA 3.1% | Solid middle-of-pack survivor |
| Muthoot Microfin | smaller | 6.2% | Recovering | Mid-pack |
| Fusion Finance | smaller | 0.7% | Among the worst-hit (Stage-3 hit 12.6%) | Walking wounded |
| Spandana Sphoorty | ₹4,420 cr | −29% | Loss-making, audit concerns flagged | The casualty |
The precedent. This exact movie has run before — twice in India (2010 Andhra Pradesh crisis nearly killed the sector; 2016 demonetisation), and each time the survivors with capital came out the other side and grew. The difference this time is the structural guardrails (exposure cap + lender cap), which is the first attempt to fix the cause (over-leverage) rather than just clean up the mess. That argues for a genuinely milder next cycle — but it is a hypothesis, not yet proven through a downturn.
Answered follow-on questions. Is the damage to share or to the spread? Neither, structurally — Satin’s spread (NIM ~13%) held and it gained share; the damage is to credit cost, which is exactly the cyclical line that’s now falling. Which segment is protected? The secured subsidiaries (housing, MSME) barely wobbled; the unsecured group-loan core is where the volatility lives. Has anyone actually moved? Yes — the recovery is in the reported numbers now, not just anticipation. Who’s on the other side? The regulator is with the survivors this time (guardrails + a credit-guarantee scheme), which is a tailwind, not a fight.
Honest verdict on the crux: takeable, leaning constructive — but with a permanent asterisk. The cycle has turned; Satin survived better than peers; the guardrails are a real structural improvement. I’d take the view that the next blow-up is milder and a few years away. But I would never call an unsecured rural lender “predictable” — the asterisk (a monsoon, an election, a new state ordinance) never comes off. This is a cyclical recovery you can lean into, not a fortress you can ignore.
② Diversification into secured + fee businesses — 🟡 promising, still small. Housing finance (₹1,267 cr, GNPA 3%), MSME (₹1,054 cr, +92% YoY), plus a new AIF fund and a tech arm. Target: 30% non-MFI by 2030. The logic is sound — graduate the disciplined MFI borrower into a secured home loan, and add fee income to dampen the cycle. But it’s 17% of the book today and the returns aren’t yet proven. Watch the non-MFI mix and whether it actually lifts consolidated RoA.
③ The Q4 profit quality — 🟡 watch. The blowout March quarter leaned partly on securitisation and treasury/forex gains. The core improved, but don’t annualise ₹162 cr.
The watch-list (check next quarter):
- Credit cost trending to the guided 3.0–3.5% (FY26 was 3.8%) — the single most important number.
- Collection efficiency holding ≥99% as new lending grows (growth can hide bad loans for a year).
- RoE crossing and holding 14–15% — the line between “cheap cyclical” and “re-rating to a quality multiple.”
- Any sign of a first dividend — the cleanest signal management trusts the cash flow.
- Non-MFI AUM mix climbing toward 30% and lifting consolidated RoA above 3%.
- Any fresh equity raise — would confirm the dilution habit and cap the upside.
QGLP scorecard (the Motilal Oswal lens) — the receipts
| # | Question | Score | Evidence |
|---|---|---|---|
| 1 | Large opportunity? | 1 | Financial inclusion — vast underbanked rural India; present in 64% of pincodes, room to grow for a decade+ |
| 2 | Industry structured favourably? | 0.5 | Commoditised, politically exposed, blow-up-prone — but new SRO guardrails are consolidating it |
| 3 | Defensible moat? | 0 | RoE beat its cost of capital in only 2 of last 10 years; no franchise, no pricing power |
| 4 | RoE & RoCE >15% consistently? | 0 | RoE 12.3%, RoCE 13.8%; RoE >15% in just 2 of 10 yrs; through-cycle avg ~9% |
| 5 | Asset-light / low capital intensity? | 0 | Capital sink — D/E ~3.8×, never-positive operating cash flow, serial equity raises |
| 6 | Favourable terms of trade (neg WC)? | 0 | N/A for a lender — it is the bank; concept inverts |
| Quality of Business | 1.5/6 | ||
| 7 | Unquestionable integrity? | 0.5 | No SEBI/RBI/auditor flags, CRAR ~25%; but zero dividends + serial dilution |
| 8 | Proven execution track record? | 0.5 | Survived 3 crises, met FY25 guidance — but volatile returns |
| 9 | Growth mindset & vision? | 1 | Clear diversification + tech strategy, AUM target raised to ₹32,000 cr by 2030 |
| 10 | Superior capital allocation? | 0.5 | Sensible subsidiaries, but reinvests + dilutes at sub-CoE returns; no dividend |
| 11 | Clear succession plan? | 0.5 | Daughter (CSO) being groomed, deep CXO bench; still key-man on H.P. Singh |
| 12 | Minority interests protected? | 0.5 | No value leakage found; but never-a-dividend is a real knock |
| Quality of Management | 3.5/6 | ||
| 13 | Structural tailwind? | 1 | Financial inclusion grows faster than GDP |
| 14 | Volume-led growth? | 0.5 | AUM-led, but yields are capped/cyclical |
| 15 | Operating leverage? | 0.5 | Cost-to-income improving; margins volatile across the cycle |
| 16 | Manageable leverage? | 0.5 | D/E ~3.8× high in absolute terms, but CRAR 25% is strong cushion |
| 17 | Market-share gain potential? | 0.5 | Gaining vs weak peers; behind CreditAccess on quality |
| 18 | Earnings growth >15% CAGR? | 0.5 | Recovery sharp, but through-cycle PAT is lumpy/unreliable |
| Growth | 3.5/6 | ||
| 19 | Relevant for next 10–15 yrs? | 0.5 | Inclusion durable; but disruption from banks/SFBs/digital + recurring blow-ups |
| 20 | Extend Competitive Advantage Period? | 0 | No durable advantage — RoE doesn’t clear CoE through cycle |
| 21 | Sustain Growth Advantage Period? | 1 | Long runway, low penetration |
| 22 | Diversification headroom? | 1 | Housing, MSME, AIF, tech — real optionality |
| 23 | Adaptive, resilient culture? | 1 | 35 yrs, three crises survived — genuinely resilient |
| Longevity | 3.5/5 | ||
| 24 | Valuation reasonable (PEG)? | 1 | 7.8× earnings, below book; PEG <1 on any sane normalised growth |
| 25 | Margin of safety? | 1 | Trades at 0.91× book; 5-yr payback ≈1× |
| Price | 2/2 | ||
| Total | 14/25 |
The pattern is stark: Price is a perfect 2/2 and Quality-of-Business is a near-zero 1.5/6. That is the whole story — a cheap stock wrapped around a mediocre business. Management (3.5) and Longevity (3.5) save it from the bottom band. It lands at 14/25: “mixed — a Good business needing capital, or quality eroding.”
Buffett lens (the Berkshire-letters read)
| # | Test | Verdict | Evidence |
|---|---|---|---|
| 1 | Good boat? (business > management) | FAIL | Through-cycle RoE ~9% < cost of capital; the boat floods every ~5 yrs. “A good managerial record is far more a function of what business boat you get into.” |
| 2 | Moat + franchise + pricing power | FAIL | Commodity lending, capped yields; RoE beat CoE 2 of 10 yrs |
| 3 | See’s test — high returns on little capital | FAIL | Capital sink: needs 3.8× leverage + repeated equity raises; FCF always negative |
| 4 | Capital allocation — the one-dollar test | FAIL | Retained everything and diluted; stock below book ⇒ rupees retained didn’t become rupees of value |
| 5 | Owner-oriented, candid management | PARTIAL | Straight talker, hit FY25 guidance; but zero dividends + serial dilution |
| 6 | Integrity / forensic check | PARTIAL | Provisioning adequate, no flags; but Q4 flattered by securitisation/treasury gains |
| 7 | Circle of competence / predictability | FAIL | You cannot forecast an MFI’s earnings 10 yrs out — hostage to monsoons, elections, ordinances. The opposite of an Inevitable |
| 8 | Mr. Market — gift or trap now? | PASS | Below book, 7.8× earnings, FIIs fled to 3.5% — a fearful price on a recovering business |
| 9 | Patience / compounding runway | PARTIAL | Long runway exists, but compounding at sub-CoE RoE with periodic 50%+ drops isn’t real compounding |
| 10 | The honest red flag | — | (below) |
Score: ~2.5 / 10. Not in the temple as a quality holding — which is the correct, unsurprising answer for a sub-cost-of-capital cyclical lender. The single PASS is Price.
The See’s test, spelled out. See’s Candy threw off $1.35bn on $32m of reinvestment because it earned high returns without swallowing capital. Satin is the mirror image: to grow its ₹15,275 cr book it borrows ₹4 for every ₹1 of equity, runs negative operating cash flow every single year (the loan book always grows faster than collections), and periodically comes back to shareholders for more equity. It is the most capital-hungry kind of business there is. Fail.
The one-dollar test, spelled out. Buffett: has each retained rupee created at least a rupee of market value? Satin has retained 100% of profits for its entire life (zero dividends) and raised fresh equity repeatedly — yet the stock trades below its book value (0.91×). That is the market saying the accumulated and raised capital is worth slightly less than the rupees put in. The test fails — not because management stole anything, but because the business can’t earn enough on capital to make retention create value.
Test 10 — the honest red flag. The strongest reason this is not a wealth creator: microfinance is structurally fragile, and Satin’s own decade proves it — a loss in FY21, profit down 76% in FY23, down 57% in FY25, and an average return on owners’ money (~9%) that doesn’t clear the ~14% an owner should demand for this much risk. Every few years a shock torches a year-plus of earnings. The cheapness (0.91× book) is cheap for a reason: the market is pricing a business that destroys economic value across a full cycle even though it makes accounting profit in the good years. The numbers support this bear case, they don’t refute it. The bull rebuttal is narrower and real: this specific operator survives every cycle, came through FY25 cleaner than peers, and the new guardrails may genuinely make the next cycle shallower — so at below book it’s a cheap claim on a recovering, well-managed survivor. Both can be true: a fragile business, a capable captain, a fair-ish price.
The framework metrics
- Economic Profit = Net Worth × (RoE − CoE) = ₹2,863 cr × (12.3% − 12%) ≈ +₹9 cr at a 12% cost of equity — essentially breakeven this (recovering) year. At a fairer 14% CoE for an unsecured rural lender: ₹2,863 cr × (12.3% − 14%) ≈ −₹49 cr. On the through-cycle average RoE of ~9%, EP is firmly negative — it destroys economic value across a full cycle.
- Terms of Trade = N/A — Satin is a lender; the negative-working-capital concept inverts (it banks its customers by definition).
- 5-yr Payback = Mcap ₹2,601 cr ÷ projected cumulative 5-yr PAT ≈ ~1.0× (assuming a normalised ~₹350 cr base growing 15%; cumulative ≈ ₹2,360 cr). Borderline-favourable — but one cyclical trough erases it.
- PEG = P/E 7.8 ÷ growth. On the FY26 rebound (+78%) PEG ≈ 0.1 (meaningless — base effect). On a sane through-cycle ~15%: PEG ≈ 0.52 — price discipline satisfied.
- RoE − CoE spread = +0.3% this year; negative through the cycle. RoE > 15% in only 2 of the last 10 years (FY19, FY24).
- Consistent/Volatile test = FAILS hard. PAT fell >10% in ~4 of the last 10 years, with two falls >50% (FY23 −76%, FY25 −57%) and an outright loss (FY21). ⇒ A Volatile wealth creator — value it on price-to-book, not price-to-earnings.
Peer comparison
| Company | Mcap (₹cr) | CMP | P/E | P/B | RoE | RoCE | Read |
|---|---|---|---|---|---|---|---|
| CreditAccess Grameen | 22,537 | 1,406 | 29.0 | 2.87× | 10.5% | 10.0% | Best-in-class; commands the premium |
| Satin Creditcare | 2,601 | 235 | 7.8 | 0.91× | 12.3% | 13.8% | Cheapest in the set; cleanest of the strugglers |
| Muthoot Microfin | 3,474 | 204 | 20.4 | 1.22× | 6.2% | 9.3% | Mid-pack, weaker RoE |
| Fusion Finance | 2,898 | 179 | 209 | 1.18× | 0.7% | 5.9% | Barely recovering off a near-loss |
| Spandana Sphoorty | 2,029 | 255 | — | 1.06× | −29.4% | −5.8% | Loss-making casualty |
The relative read flips the absolute one — and it’s the most interesting thing here. On the absolute QGLP/Buffett lens, Satin is a mediocre business. But within its own beaten-down asset class, it is the cheapest stock (0.91× book — the only one below book) attached to the best current returns of the survivor group (RoE 12.3% beats Muthoot 6%, Fusion ~1%, Spandana negative). Only CreditAccess trades richer (2.9× book), and it earns that with cleaner, higher-quality returns. So a patient value/Buffett investor sees “fragile business, fair price.” A sector-allocator sees “if you’re going to own an MFI recovery at all, Satin is the value pick of the survivors — cheaper than peers, cleaner asset quality, faster rebound.” Those two answers don’t contradict; they answer different questions.
Latest quarter & what’s happening now
Q4 FY26 (reported 12 May 2026) was Satin’s strongest quarter in memory: consolidated PAT ₹162 cr (+640% YoY, +125% QoQ), full-year FY26 PAT ₹330 cr (+79%), consolidated AUM ₹15,275 cr (+19%). RoA 2.6%, RoE 12.3% for the year (Q4 alone: RoA 4.7%, RoE 23.3%). Standalone GNPA 3.1%, credit cost down to 3.8%, CRAR 25.4%.
Concall takeaways: (1) Management calls the sector “past its stress peak” and is leaning into the recovery — FY27 guidance of 15–20% standalone AUM growth and credit cost down to 3.0–3.5% [MEDIUM]. (2) The subsidiaries (housing, MSME) both crossed ₹1,000 cr AUM and are being pushed as the future RoA kickers [MEDIUM]. (3) The Q4 profit was partly flattered by ₹144 cr of securitisation/derecognition + treasury/forex gains — management insists “no one-off” in the core, but the quarter shouldn’t be annualised [HARD, from transcript]. (4) Long-term AUM target raised from ₹25,000 cr to ₹32,000 cr by 2030 [SOFT].
Where the two lenses agree — and disagree
They agree almost completely, which is itself the signal: QGLP 14/25 and Buffett 2.5/10 both say mediocre-quality, capital-hungry, cyclical business whose only attraction is price. Both flag the same single bright spot — Price (QGLP’s Price pillar 2/2; Buffett’s Mr. Market PASS). Both flag the same fatal weaknesses — no moat, sub-CoE returns, fragility.
The one genuine divergence is the absolute-vs-relative valuation read (see Peer comparison): the Buffett/QGLP absolute lens says “fragile business, don’t confuse cheap with good,” while the relative lens says “cheapest, cleanest survivor in a recovering sector.” That’s not the two masters disagreeing — it’s the difference between a buy-and-hold-forever owner and a cyclical-value allocator. Be honest about which game you’re playing. This is a cyclical/value/mean-reversion idea, not a quality-compounder idea.
Margin-of-safety price band
Value a volatile lender on book value, not earnings (its earnings lie in both directions across the cycle). Book value is ₹259.
- Cheap: ₹200–235 (≈0.77–0.91× book). Below book — Mr. Market is fearful. This is roughly where it trades today, and where the margin of safety is real if the recovery holds.
- Fair: ₹260–300 (≈1.0–1.15× book). What a middling MFI earning a normalised ~12–14% RoE deserves once the recovery is proven.
- Demanding: >₹340 (>1.3× book). You’d be paying a quality multiple for a business that hasn’t earned it. (For reference, best-in-class CreditAccess gets ~2.9× book — Satin is not that business.)
CMP ₹235 sits at the cheap-to-fair boundary — modestly below book. Plainly: this is a fair-ish price for a fragile business, not a wonderful business at a wonderful price. The catch worth stating loudly — the stock is already up ~77% from its ₹133 low, so the deep-fear discount has largely closed. The easy mean-reversion is behind it; from here you’re paying for the recovery to continue.
Conviction texture
The bull case, at its strongest: A 35-year survivor that came through the worst MFI cycle in years cleaner than its peers, trading below book while it’s recovering — credit costs falling, collections at 99.9%, the sector growing again, new regulatory guardrails that may genuinely make the next downturn shallower. It’s the cheapest, best-quality name among the walking-wounded survivors, with real optionality from fast-growing secured subsidiaries. If RoE settles into the mid-teens and holds, a re-rating from 0.9× to ~1.3× book is ~40% upside before any earnings growth.
The bear case, at its strongest (the red flag): Microfinance is structurally fragile and Satin’s own decade proves it — a loss, two 50%+ profit collapses, and a through-cycle return on equity (~9%) that doesn’t clear the cost of the risk. It has never paid a dividend, dilutes owners repeatedly, and trades below book because the market correctly prices a business that destroys economic value across a full cycle. The cheapness already shrank by 77% off the bottom; the next village-level shock — a monsoon, an election, a state ordinance — is a question of when, not if, and it will torch a year of earnings.
What the numbers actually support: Both. This is a fair price for a fragile, capable survivor mid-recovery — a legitimate cyclical-value idea, an illegitimate quality-compounder idea. The thing to watch is whether RoE can hold in the mid-teens for two clean years and whether a first dividend ever appears; that’s the line between “cheap forever” and “re-rates.” Until then, treat it as exactly what it is — a scarred microlender bought below book, betting the storms stay a few years apart. No buy/sell — your call on which game you’re playing.
Sources
- Screener: https://www.screener.in/company/SATIN/consolidated/ (snapshot fetched 2026-06-20)
- Q4 FY26 earnings call transcript, 12 May 2026 (Satin Creditcare / BSE filing)
- Annual Report FY25 (Chairman’s statement + MD&A, BSE filing)
- MFIN 57th Micrometer (Q4 FY26) — sector recovery data, via Business Standard, 12 Jun 2026
- ICRA sector outlook (credit cost FY26–27), via Business Standard, 8 Sep 2025
- CareEdge & ICRA rating rationales on SATIN (asset quality, CRAR), Jul 2025
- Peer snapshots (CreditAccess Grameen, Fusion Finance, Spandana Sphoorty, Muthoot Microfin) — screener, fetched 2026-06-20
- Assumptions: Cost of equity 12% (base; 14% noted as fairer for an unsecured MFI); through-cycle normalised PAT growth 15% for payback/PEG. Valuation framed on price-to-book given the failed consistency test.